BIT Capital GmbH Buys Shares of 25,422 AnaptysBio, Inc. (NASDAQ:ANAB)

Key Points

• BIT Capital GmbH invested approximately $473,000 in AnaptysBio, acquiring 25,422 shares and representing 0.09% ownership as of the latest SEC filing.
• Multiple institutional investors have increased their stakes in AnaptysBio in the first quarter, with DCF Advisers LLC and Victory Capital Management Inc. making notable new investments.
• Analysts have a consensus rating of "Moderate Buy" for AnaptysBio, with target prices significantly raised by firms such as JPMorgan and Guggenheim, reflecting growing confidence in the stock.

BIT Capital GmbH acquired a new stake in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) during the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 25,422 shares of the biotechnology company's stock, valued at approximately $473,000. BIT Capital GmbH owned approximately 0.09% of AnaptysBio at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in ANAB. US Bancorp DE lifted its position in AnaptysBio by 126.5% during the 1st quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company's stock worth $33,000 after buying an additional 979 shares in the last quarter. Farther Finance Advisors LLC lifted its position in AnaptysBio by 9,778.9% during the 1st quarter. Farther Finance Advisors LLC now owns 1,877 shares of the biotechnology company's stock worth $35,000 after buying an additional 1,858 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in AnaptysBio by 131.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company's stock worth $36,000 after buying an additional 1,531 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in AnaptysBio during the 4th quarter worth about $40,000. Finally, Virtus ETF Advisers LLC lifted its position in AnaptysBio by 24.7% during the 4th quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company's stock worth $63,000 after buying an additional 936 shares in the last quarter.

AnaptysBio Stock Performance

ANAB traded down $0.49 on Tuesday, reaching $23.74. The company had a trading volume of 99,045 shares, compared to its average volume of 779,884. AnaptysBio, Inc. has a fifty-two week low of $12.21 and a fifty-two week high of $41.31. The stock has a market cap of $697.60 million, a P/E ratio of -4.88 and a beta of -0.20. The company's fifty day moving average is $24.16 and its 200 day moving average is $20.35.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its earnings results on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.30) by $0.02. The firm had revenue of $27.77 million for the quarter, compared to analyst estimates of $15.27 million. AnaptysBio had a negative net margin of 125.70% and a negative return on equity of 282.47%. On average, sell-side analysts expect that AnaptysBio, Inc. will post -6.08 EPS for the current year.

Insider Buying and Selling

In related news, Director Hollings Renton sold 20,925 shares of the firm's stock in a transaction on Wednesday, July 2nd. The stock was sold at an average price of $23.57, for a total value of $493,202.25. Following the transaction, the director owned 4,965 shares in the company, valued at approximately $117,025.05. This trade represents a 80.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 33.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. HC Wainwright raised shares of AnaptysBio from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $22.00 to $38.00 in a research report on Wednesday, June 4th. JPMorgan Chase & Co. boosted their price objective on shares of AnaptysBio from $42.00 to $80.00 and gave the stock an "overweight" rating in a research note on Thursday, July 24th. Wedbush restated an "outperform" rating and set a $40.00 price objective on shares of AnaptysBio in a research note on Thursday, May 29th. Finally, Guggenheim restated a "buy" rating and set a $90.00 price objective (up from $54.00) on shares of AnaptysBio in a research note on Wednesday, May 28th. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, AnaptysBio currently has an average rating of "Moderate Buy" and an average target price of $47.13.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.